By Thomas Fuller, CEO & Managing Partner, Epsen Fuller Group
New research reveals the severity of the gender gap in the boardroom and C-suite in pharma, biotech, and medical devices companies. Executive search and leadership consulting firm Epsen Fuller Group|IMD conducted the research, which included 423 publicly held, U.S.-based, life science companies ranging in size from micro-cap to large-cap.
This is an important study in that, while most widely published studies on gender diversity in the corporate world focus only on the Fortune 500, FTSE 100, or other lists of exclusively mega-sized enterprises, Epsen Fuller’s study represents a broad cross-section of company size, as defined by market capitalization, in a specific industry sector. As some reports show strides are being made, this study clearly identifies there is still a persistent gap in male and female representation on Boards and in C-Suites in the ever-growing life science sector.
Click here for more information on the study.
Also, see these Life Science Leader articles related to this topic: